CRISPR and Vertex Shares Surge After FDA Approves Casgevy for Younger Patients
CRSP shares jumped 8% following FDA approval of Casgevy for children ages 2 and up, signaling a significant market opportunity.
Zymeworks' $929 Million Acquisition of Theravance Biopharma: Implications for Investors
Zymeworks' strategic $929M acquisition of Theravance Biopharma at $17/share highlights key trends in the biotech sector.
Viridian Therapeutics Achieves Milestone with FDA Approval of Lumvoa: What Investors Need to Know
Viridian Therapeutics' Lumvoa receives FDA approval, boosting stock by 6% in after-hours trading. Insights on UBS rating and implications fo…
Larimar Therapeutics Faces Setback with Partial BLA Submission for Nomlabofusp
Larimar Therapeutics' stock slides after a partial BLA submission delays FDA review timelines for nomlabofusp.
Capricor Therapeutics: FDA Advisory Meeting for Duchenne Therapy on the Horizon
Capricor Therapeutics seeks FDA approval for Deramiocel, a promising cell therapy for Duchenne muscular dystrophy, backed by five-year data.
Replimune's FDA BLA Acceptance: A Game Changer for Investors?
Replimune's FDA acceptance of its BLA for RP1 signals potential growth for investors as regulatory hurdles are cleared.
Insurance Coverage Concerns for GLP-1 Weight Loss Pills: What Investors Should Know
As consumer demand for GLP-1 weight-loss pills surges, insurance coverage limitations may impact revenue for $NVO and $LLY.
Replimune's FDA BLA Resubmission: A Game-Changer for Biotech Investors
Replimune's resubmission acceptance by the FDA could redefine investor sentiment and market dynamics for $REPL.
Aptorum Group's Strategic Move in Alzheimer's Biomarkers: A Game Changer for Investors?
Aptorum Group's collaboration with AlzLabs could reshape Alzheimer's diagnostics and impact the small-cap pharma market.
AbbVie’s $10.9 Billion Bet on Apogee: What It Means for Investors
AbbVie's $10.9 billion acquisition of Apogee Therapeutics reshapes its pipeline and reflects broader M&A trends in pharma.
Analyst Upgrade: Incyte Stock's New Market Perform Rating
BMO Capital's upgrade of Incyte to Market Perform reflects strategic progress but may pose risks for investors.
REGENXBIO's Path Forward: FDA Alignment on Gene Therapy Resubmission
REGENXBIO aligns with the FDA on gene therapy resubmission, paving the way for NAVSUNLI's future.